ResultsIQ

ResultsIQ › Latest results › Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd strategy deck summary

NSE: SUDARSHAN · BSE: 543828

Strategy deck of 7 Nov 2026, summarised by AI from the filing.

Sudarshan Pharma's half-year to September 2026 revenue was ₹391.39 cr with PAT of ₹13.39 cr, and it targets at least ₹100 cr of exports in FY 26-27.

Key takeaways

  1. Export target Management targets minimum ₹100 cr of exports in FY 26-27, after ₹21.85 cr in FY 25-26.
  2. Margin lift EBITDA margin rose to 10.13% from 7.42% in September 2025, with gross margin at 14.77% from 10.38%.

Original filing on BSE

Sudarshan Pharma Industries Ltd Q2 FY27 results

As filed: Revenue ₹205 cr, EBITDA ₹20.7 cr, PAT ₹7.8 cr, EBITDA margin 10.1%.

Not scored. No result for the same quarter last year.

Sudarshan Pharma Industries Ltd earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.